CMS attributed the increased rate of spending on retail prescription drugs to growth in Medicare and out-of-pocket spending during the period while Medicaid and private health insurance spending slowed.
Why the U.S. spends more on healthcare with worse results; Alnylam goes it alone on rare disease therapy; MorphoSys hopes for accelerated approval on MOR208.
Global adspend growth to accelerate to 4.7% in ‘stellar’ 2018
50% of consumers say they will share their health data with tech giants; pharma CEOs expect pricing proposal from Trump administration; FDA approves generic versions of Strattera
Pricing pressure is the new new normal for drugmakers